Intra-Cellular Therapies, Inc.
ORGANIC COMPOUNDS
Last updated:
Abstract:
The disclosure relates to methods of administering comprising administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment and/or prophylaxis of renal disorders, such as chronic kidney disease. Related compounds and methods of making are further defined.
Status:
Application
Type:
Utility
Filling date:
21 Aug 2020
Issue date:
8 Sep 2022